You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Cytomics said its January Varseta M update will disclose first overall survival data, plus safety, ORR and PFS from 40 dose-optimization patients; 113 patients are enrolled in the phase one study.
Cytomex Therapeutics plans an integrated Varsetta M update in January, including a first look at overall survival, and aims to begin its first potential registrational study in the first half of 2027.
CytomX Therapeutics said Varseta-M received FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer and ended Q3 2026 with $348.0 million in cash, cash equivalents and investments, providing cash runway into the second half of 2028.
CytomX reports Varseta-M received FDA fast track designation for relapsed/refractory metastatic colorectal cancer; expansion data showed confirmed response rates of 20% at 8.6 mg/kg and 32% at 10 mg/kg, and additional dose-selection data are expected in January of 2027.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Varseta-M received Fast Track designation and advanced toward a January 2027 update, a potential 1H 2027 registrational study, combination development and expansion into additional gastrointestinal tumors, while CX-801 enrollment progressed. CytomX ended Q3 with $348.0 million, including the $37 million Regeneron payment, and expects runway into the second half of 2028, but revenue declined, operating expenses increased, the net loss widened and grade 3 diarrhea remained a key safety risk.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTMX
this stock
CytomX Therapeutics, Inc.
|
$444.73M | -52.1% | -44.8% | — | 20.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Cytomics said its January Varseta M update will disclose first overall survival data, plus safety, ORR and PFS from 40 dose-optimization patients; 113 patients are enrolled in the phase one study.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTMX | -6.9% | -10.5% | -44.7% | -12.8% | -52.1% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -9.4% | -9.4% | -45.2% | -12.6% | -62.7% |
